Search Results for "hATTR"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Vutrisiran: Survival and Mortality

Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.

Patisiran: APOLLO-B OLE Study

Standard response letter on the APOLLO-B OLE study of patisiran.

Patisiran: Use in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy

Standard response letter on the use of patisiran in patients with hATTR and mixed phenotype from the APOLLO-B study.

Givosiran: Hemin Use

Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.

Vutrisiran: Pain in Extremity

Standard response letter on vutrisiran and the adverse event of pain in extremity.

Vutrisiran: Use in Patients with Renal Impairment

Standard response letter on vutrisiran and use in patients with renal impairment.

Transition between Patisiran and Vutrisiran

Standard response letter on transitioning between patisiran and vutrisiran therapy.

Vutrisiran: HELIOS-A Study

Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.

Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile

Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.

Vutrisiran: Randomized Treatment Extension Period of the HELIOS-A Study

Standard response letter on vutrisiran and results from a 9-month analysis of the randomized treatment extension period of HELIOS-A.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "hATTR"

Vutrisiran: Survival and Mortality Standard response letter on mortality and survival data from the HELIOS studies of vutrisiran.

Patisiran: APOLLO-B OLE Study Standard response letter on the APOLLO-B OLE study of patisiran.

Patisiran: Use in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy Standard response letter on the use of patisiran in patients with hATTR and mixed phenotype from the APOLLO-B study.

Givosiran: Hemin Use Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.

Vutrisiran: Pain in Extremity Standard response letter on vutrisiran and the adverse event of pain in extremity.

Vutrisiran: Use in Patients with Renal Impairment Standard response letter on vutrisiran and use in patients with renal impairment.

Transition between Patisiran and Vutrisiran Standard response letter on transitioning between patisiran and vutrisiran therapy.

Vutrisiran: HELIOS-A Study Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.

Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.

Vutrisiran: Randomized Treatment Extension Period of the HELIOS-A Study Standard response letter on vutrisiran and results from a 9-month analysis of the randomized treatment extension period of HELIOS-A.